GSK has agreed to acquire RAPT Therapeutics, adding food allergy drug candidates to its pipeline. The company has received ...
Jan 20 (Reuters) - Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
By Pushkala Aripaka and Bhanvi Satija Jan 20 (Reuters) - Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, ...
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
The European Commission has approved GSK’s respiratory syncytial virus (RSV) vaccine for use in all adults, the drugs giant ...
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more ...
The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results